- Title: Subtitle
- Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1
- Creators
- Frederick L. Locke - Moffitt Cancer CenterArmin Ghobadi - Washington University in St. LouisLazaros J. Lekakis - University of Miami Health SystemDavid B. Miklos - Stanford UniversityCaron A. Jacobson - Dana-Farber Cancer InstituteEric Jacobsen - Dana-Farber Cancer InstituteIra Braunschweig - Albert Einstein College of MedicineOlalekan O. Oluwole - Vanderbilt UniversityTanya Siddiqi - City Of Hope National Medical CenterYi Lin - Mayo ClinicPatrick M. Reagan - University of RochesterUmar Farooq - University of IowaAbhinav Deol - Wayne State UniversityAdrian Bot - KiteJohn M. RossiYizhou JiangAllen Xue - KiteWilliam Y. Go - KiteSattva S. Neelapu - The University of Texas MD Anderson Cancer Center
- Resource Type
- Abstract
- Publication Details
- Clinical lymphoma, myeloma and leukemia, Vol.18, p.S276
- DOI
- 10.1016/j.clml.2018.07.203
- ISSN
- 2152-2650
- eISSN
- 2152-2669
- Language
- English
- Date published
- 09/2018
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984362746602771
Abstract
Axicabtagene Ciloleucel in Patients with Refractory Large B Cell Lymphoma: Outcomes by Prior Lines of Therapy in the Pivotal Phase 2 Study, ZUMA-1
Clinical lymphoma, myeloma and leukemia, Vol.18, p.S276
09/2018
DOI: 10.1016/j.clml.2018.07.203
Details
Metrics
8 Record Views